All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 35 points (-0.2%) at 17,589 as of Tuesday, Oct. 27, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 752 issues advancing vs. 2,254 declining with 128 unchanged.

The Drugs industry currently sits down 0.4% versus the S&P 500, which is down 0.4%. A company within the industry that fell today was

Novartis

(

NVS

), up 2.2%. Top gainers within the industry include

United Therapeutics

(

UTHR

), up 9.5%,

Shire

(

SHPG

), up 7.1%,

Allergan

(

AGN

), up 3.3%,

Alexion Pharmaceuticals

(

ALXN

), up 2.4% and

AbbVie

(

ABBV

), up 2.0%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

AstraZeneca

(

AZN

) is one of the companies pushing the Drugs industry lower today. As of noon trading, AstraZeneca is down $0.18 (-0.6%) to $31.28 on average volume. Thus far, 1.1 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $31.28-$31.54 after having opened the day at $31.35 as compared to the previous trading day's close of $31.46.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. AstraZeneca has a market cap of $79.3 billion and is part of the health care sector. Shares are down 10.9% year-to-date as of the close of trading on Monday. Currently there are 3 analysts that rate AstraZeneca a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

AstraZeneca

as a

hold

. The company's strengths can be seen in multiple areas, such as its expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and weak operating cash flow. Get the full

AstraZeneca Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

GlaxoSmithKline

(

GSK

) is down $0.21 (-0.5%) to $41.86 on average volume. Thus far, 1.8 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 3.9 million shares. The stock has ranged in price between $41.85-$42.18 after having opened the day at $41.90 as compared to the previous trading day's close of $42.07.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $91.4 billion and is part of the health care sector. Shares are down 1.5% year-to-date as of the close of trading on Monday. Currently there are 3 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates

GlaxoSmithKline

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

GlaxoSmithKline Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Teva Pharmaceutical Industries

(

TEVA

) is down $0.62 (-1.0%) to $59.09 on average volume. Thus far, 2.3 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5.8 million shares. The stock has ranged in price between $58.99-$60.36 after having opened the day at $59.64 as compared to the previous trading day's close of $59.71.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. Teva Pharmaceutical Industries has a market cap of $50.0 billion and is part of the health care sector. Shares are up 3.5% year-to-date as of the close of trading on Monday. Currently there are 12 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Teva Pharmaceutical Industries

as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, expanding profit margins, increase in stock price during the past year and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Teva Pharmaceutical Industries Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).